JPH 203Alternative Names: JPH-203SBECD; JPH203
Latest Information Update: 19 Feb 2015
At a glance
- Originator J-Pharma
- Class Antineoplastics
- Mechanism of Action Amino acid transport system L inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 19 Feb 2015 JPH 203 has patent protection in Japan
- 19 Jan 2015 Phase-I clinical trials in Solid tumours (Metastatic disease) in Japan (IV) (UMIN000016546)